ClinicalTrials.gg
CompletedNCT07297732Updated Mar 31, 2026

A Study to Investigate the Tooth Whitening and Dentin Hypersensitivity Effectiveness of Two Experimental Toothpastes

An interventional study of Test Toothpaste 1 and Test Toothpaste 2 in Dentin Hypersensitivity, sponsored by HALEON. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by HALEON · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 21 studies in Dentin Sensitivity by HALEON — 3 open to participants now, 3 under way, none of them phase 3. Dentin Sensitivity · HALEON.

Enrollment
7th of 20
254 · median 185
Started
2025
with 3 others
No phase
18 of 21
2 open now
Registered
13th of 21
by date

Among the 21 studies in Dentin Sensitivity by HALEON, this one is the 7th largest by enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2025, is one of 18 with no phase, and was the 13th registered.

Dentin Sensitivity

292 studies on the registry are indexed under Dentin Sensitivity; 49 are open to participants now.

Browse Dentin Sensitivity studies →

Open to participants now

3 of the 21 studies in Dentin Sensitivity by HALEON are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 20 Dentin Sensitivity studies recruiting now, 6 (30%) set no upper age limit and 13 (65%) stop at 75 or younger; 2 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Dentin Sensitivity by HALEON, or all of them as a file.
02

Study summary

The aim of this exploratory clinical study is to investigate the tooth whitening potential, Dentin Hypersensitivity (DH) efficacy, and oral tolerability of two experimental toothpastes in a DH population with appropriate tooth shade and dental stain levels for the evaluation of whitening performance.

Read the detailed description

This will be a single center, randomized, controlled, examiner-blind, 3-treatment arm, stratified (Baseline mean VITA Bleached Guide 3D-MASTER score), parallel design, clinical study in healthy participants, aged 18-65 years inclusive, with sufficient tooth discoloration/surface stain to evaluate the whitening potential of the experimental formulations, and self-reported/clinically diagnosed dentin hypersensitivity. Participants who meet the required study criteria at Screening and Baseline will be randomized to one of three study toothpastes. Approximately 105 qualifying participants will be stratified and randomized to study treatment (approximately 35 participants per treatment group).

03

Conditions studied

  • Dentin Hypersensitivity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated before any study procedures are performed.
  • Participant is biologically male or female.
  • Participant is 18 to 65 years of age, inclusive, at the time of signing the consent form.
  • Participant is willing and able to comply with the study visit schedule, product usage instructions, lifestyle restrictions and other study procedures.
  • Participant is in good general, oral and mental health with, in the opinion of the investigator or medically qualified designee, no or relevant abnormalities in self-reported medical history (example, a medical condition confirmed to be causing xerostomia), or upon oral examination, that would impact their safety or wellbeing, or the outcomes of the study, if they were to participate in the study, or affect their ability to understand and follow study requirements.
  • Participant must have History of tooth sensitivity lasting more than six months but not more than 10 years (self-reported) and must have good general oral health, with a minimum of 20 natural teeth.
  • Participant must have minimum of 2 accessible, non-adjacent teeth (incisors, canines, premolars), in different quadrants

Exclusion criteria

Exclusion Criteria:

  • Participant is an employee of the study site directly involved in the conduct of the study, or an employee of the study site otherwise supervised by the investigator, or a member of their immediate family.
  • Participant is an employee of the sponsor directly involved in the conduct of the study or a member of their immediate family.
  • Female participant who is pregnant (self-reported) or intending to become pregnant during the study (self-reported) or who is who is breastfeeding (self-reported).
  • Participant with known or suspected intolerance or to any of the study products (Acclimatization Toothpaste or study toothpastes), any of their stated ingredients or closely related compounds (self-reported).
  • Participant with a recent history (within the last year) of alcohol or other substance abuse (self-reported).
  • Participant is participating in, or has participated in, other studies (including non-medicinal studies) involving an product (IP) within 30 days of Screening (Visit 1) or plans to participate in other studies (including non-medicinal studies) during this study (self-reported).
  • Participant has participated in a tooth sensitivity study within 8 weeks of Screening (Visit 1) (self-reported).
  • Participant is currently using an oral care product indicated for DH relief or care of sensitive teeth or has used an anti-hypersensitivity oral care product within 8 weeks of Screening (Visit 1) (self-reported).
  • Participant is currently using an oral care product primarily intended for tooth whitening benefits or has used such a product within 8 weeks of Screening (Visit 1) (self-reported).
  • Participant has had professional tooth de-sensitizing treatment within 8 weeks of Screening (Visit 1) (self-reported).
  • Participant is taking daily doses of medications/treatments (self-reported) which, in the opinion of the investigator or medically qualified designee, could interfere with their perception of tooth sensitivity (example, analgesics, anticonvulsants, antihistamines that cause marked or moderate sedation, sedatives, tranquilizers, antidepressants, mood-altering and anti-inflammatory drugs).
  • Participant is taking daily doses of a medication (self-reported) which, in the opinion of the investigator or medically qualified designee, is causing xerostomia.
  • Participant requires antibiotic prophylaxis for dental procedures (self-reported).
  • Participant has had a tooth whitening procedure (professional or in-home treatment) within 12 months of Screening (Visit 1) (self-reported).
  • Participant has had dental prophylaxis within 8 weeks of Screening (Visit 1) (self-reported).
  • Participant has had treatment for periodontal disease (including surgery) within 12 months of Screening (Visit 1) (self-reported).
  • Participant has had scaling or root planing within 3 months of Screening (Visit 1) (self-reported).
  • Participant with, in the opinion of the investigator or medically qualified designee, gross periodontal disease.
  • Participant with a tongue or lip piercing.
  • Participant with, in the opinion of the investigator or medically qualified designee, evidence of gross intra-oral neglect or the need for extensive dental therapy.
  • Participant with evidence of current/recent active dental caries or (self-reported) treatment for decay within 12 months of Screening (Visit 1).
  • Participant with a fixed or removable partial prosthesis, multiple dental implants, fixed or removable orthodontic braces/bands and/or a fixed orthodontic retainer which, in the opinion of the investigator or dentally qualified designee, could impact study outcomes.
  • Specific dentition exclusions: For eligible teeth (DH assessment)

    1. Tooth with evidence of current/recent caries.
    2. Tooth with treatment for decay within 12 months of Screening (Visit 1) (self-reported).
    3. Tooth with exposed dentin and deep, defective or facial restorations.
    4. Tooth with a full crown or veneer.
    5. Tooth adjacent to a bridge abutment or crown which, in the opinion of the investigator or dentally qualified designee, could impact study outcomes.
    6. Sensitive tooth with contributing etiologies other than EAR to exposed dentin.
    7. Sensitive tooth not expected to benefit from use of an anti-hypersensitivity toothpaste, in the opinion of the investigator or dentally qualified designee.
  • Participant has taken antibiotics in the 2 weeks prior to Screening (Visit 1) (self-reported).
  • Participant has taken antibiotics in the 2 weeks prior to Baseline (Visit 2), that is, during the 2-week Acclimatization Period (self-reported).
  • Participant has previously been enrolled in this study.
  • Participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
254 participants (actual)

Study arms

  • Experimental
    Test Toothpaste 1

    Participants will be instructed to brush the entire dentition thoroughly using Test toothpaste 1 for 2-timed minutes, twice daily (morning and evening) for 8 weeks, making sure to brush all sensitive areas of the teeth.

    Drug: Test Toothpaste 1

  • Experimental
    Test Toothpaste 2

    Participants will be instructed to brush the entire dentition thoroughly using Test toothpaste 2 for 2-timed minutes, twice daily (morning and evening) for 8 weeks, making sure to brush all sensitive areas of the teeth.

    Drug: Test Toothpaste 2

  • Active comparator
    Reference Toothpaste

    Participants will be instructed to brush the entire dentition thoroughly using Reference toothpaste for 2-timed minutes, twice daily (morning and evening) for 8 weeks, making sure to brush all sensitive areas of the teeth.

    Drug: Reference Toothpaste

Interventions

  • DrugTest Toothpaste 1

    Toothpaste containing Potassium nitrate

  • DrugTest Toothpaste 2

    Toothpaste containing Potassium nitrate

  • DrugReference Toothpaste

    Regular fluoride toothpaste

06

What researchers measure

Primary outcomes

  1. Mean VITA Shade Score at Baseline, Weeks 1, 2, 4 and 8

    Tooth color of the facial surfaces of the six anterior maxillary teeth will be visually assessed using the VITA Bleachedguide 3D-MASTER shade guide. It consists of a value-ranked ordered scale from 1 (lightest) to 29 (darkest). The shade of each assessable tooth surface/region will be scored by the clinical examiner with reference to the guide, where lower score indicates improvement.

    Time frame: Baseline, Weeks 1, 2, 4 and 8

  2. Mean Total Modified Lobene Stain Index (MLSI) Score at Baseline, Weeks 1, 2, 4 and 8

    Dental stain will be visually assessed for the facial surfaces of the teeth (incisors and canines) using the MLSI. For each tooth surface assessed, Area (A) and Intensity (I) of dental stain will be scored separately on the scale of 0 to 3 and the mean total score will be presented, where 0=Area with no stain, 1=Stain covering up to one third of area and light intensity stain, 2=Stain covering up to two thirds of area and moderate intensity stain, 3=Stain covering more than two thirds of area and heavy intensity stain. Total MLSI score = Area score multiplied by Intensity score and ranging from 0 to 9, where lower score indicates improvement.

    Time frame: Baseline, Weeks 1, 2, 4 and 8

Secondary outcomes

  1. Schiff Sensitivity Score at Baseline, Week 4 and Week 8

    Evaporative (air) sensitivity will be assessed by participant's response to an evaporative (air) stimulus after stimulation of 2 selected test teeth. Response of participant will be scored using Schiff sensitivity scale which ranges from 0-3, where 0=Does not respond to air stimulation; 1=Responds to air stimulus but does not request discontinuation of stimulus; 2=Responds to air stimulus and requests discontinuation or moves from stimulus; 3=Responds to stimulus, considers stimulus to be painful and requests discontinuation of the stimulus. The lower score indicates improvement.

    Time frame: Baseline, Week 4 and 8

  2. Tactile Threshold at Baseline, Week 4 and Week 8

    The tactile sensitivity will be assessed by administrating a constant pressure using a Yeaple probe. The tactile threshold is the maximum pressure applied without the participant reporting pain or discomfort. The tactile threshold for 2 selected test teeth will be determined by asking the participant whether the sensation caused discomfort. The pressure setting at which the participant gives two consecutives 'yes' responses will be recorded as the tactile threshold. The greater the tactile threshold, the less sensitive the tooth.

    Time frame: Baseline, Week 4 and 8

07

Study locations

1 site
  • Silverstone Research Group
    Las Vegas, Nevada 89146, United States
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Mar 2026, 3 months.

Of 34 industry-sponsored interventional studies with no phase under Dentin Sensitivity, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 6. This study's 3 months is close to that.

Counting every sponsor, half of 146 studies reached it within 6 months; a quarter within 3 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Dec 22, 2025
StartActual
Dec 15, 2025
Primary completionActual
Mar 19, 2026
CompletionActual
Mar 19, 2026
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07297732
Lead sponsor
HALEON
Responsible party
Sponsor
First posted
Dec 22, 2025
Start date
Dec 15, 2025
Primary completion
Mar 19, 2026
Completion
Mar 19, 2026
Last update
Mar 31, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion